Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081654 | 0.85 | ADORA1 (0.47) | ADORA1ESR2NR1H2USP30USP2 | |
| SCHEMBL25305107 | 0.85 | ESR2 (0.44) | ADORA1ESR2NR1H2USP30USP2 | |
| SCHEMBL30965884 | 0.84 | ESR2 (0.41) | ADORA1ESR2NR1H2USP30USP2 | |
| SCHEMBL30340772 | 0.84 | TSHR (0.36) | SMN1; SMN2MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL11981955 | 0.82 | NR1H2 (0.41) | ADORA1ESR2NR1H2USP30USP2 | |
| SCHEMBL2483591 | 0.78 | ADORA1 (0.47) | ADORA1ESR2NR1H2USP30USP2 | |
| SCHEMBL29023102 | 0.74 | USP30 (0.37) | ESR2NR1H2USP30USP2SMN1; SMN2 | |
| SCHEMBL22204312 | 0.74 | PARP1 (0.41) | ADORA1ESR2NR1H2USP30MAPT | |
| SCHEMBL30340769 | 0.74 | TSHR (0.36) | SMN1; SMN2MAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL2118147 | 0.74 | ESR2 (0.46) | ADORA1ESR2NR1H2USP30MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | ADORA1 155/4885ESR2 2484/4885NR1H2 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.